HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Shapiro, B. E. Articles by Natowicz, M. R. Search for Related Content PubMed PubMed Citation Articles by Shapiro, B. E. Articles by Natowicz, M. R. Related Collections Lipidoses

Late-onset Tay–Sachs disease: Adverse effects of medications and implications for treatment

From the Neuromuscular Division, Department of Neurology (B.E.S., J.A.F.-F., K.A), and Department of Psychiatry (S.H.-F.), University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH; and Genomic Medicine Institute and Departments of Neurology and Pediatrics, Cleveland Clinic Foundation, Cleveland, OH (M.R.N.).

Address correspondence and reprint requests to Dr. Barbara E. Shapiro, Director, Neuromuscular Research, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106-5098; e-mail: bes002{at}aol.com

The authors conducted a retrospective and brief prospective study of adverse effects of approximately 350 medications in 44 adults with late-onset Tay–Sachs disease (LOTS). Some medications were relatively safe, whereas others, particularly haloperidol, risperidone, and chlorpromazine, were associated with neurologic worsening.

Supported by a grant from The Mt. Sinai Health Care Foundation, Cleveland, OH.

Disclosure: The authors report no conflicts of interest.

Presented at The American Academy of Neurology, Honolulu, Hawaii, 2003.

Received March 1, 2006. Accepted in final form May 9, 2006.